Schneeweiss, A., Ettl, J., Lüftner, D., Beckmann, M. W., Belleville, E., Fasching, P. A., Fehm, T. N., Geberth, M., Häberle, L., Hadji, P., Hartkopf, A. D., Hielscher, C., Huober, J., Ruckhäberle, E., Janni, W., Kolberg, H. C., Kurbacher, C. M., Klein, E., Lux, M. P., Müller, V., Nabieva, N., Overkamp, F., Tesch, H., Laakmann, E., Taran, F., Seitz, J., Thomssen, C., Untch, M., Wimberger, P., Wuerstlein, R., Volz, B., Wallwiener, D., Wallwiener, M., & Brucker, S. Y. (2021). corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". Breast, 55, 138–139. http://access.bl.uk/ark:/81055/vdc_100120460565.0x000010